Most Recent Articles by Diana Ernst, RPh
A phase 3 study evaluating HIV patients who switched to treatment with Biktarvy found this combination therapy to be statistically noninferior to a regimen containing abacavir,
The recommendation was made after the FDA reviewed the results of a 10-year follow-up of the CLARICOR trial, which investigated the effects of clarithromycin in patients with stable coronary heart disease.
The recommendation follows the presentation of positive results from a US study in children between the ages of 2 to <4 years evaluating the shedding and antibody responses of the H1N1 strain in the live attenuated influenza vaccine.
The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.
Individuals who have previously received 2 doses of a mumps-containing vaccine should receive a third dose if at increased risk for developing mumps.
More Articles by Diana Ernst, RPh
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Generic HIV Medicines: Boon or Bust?
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- It Costs $2.2 Billion a Year to Treat Antibiotic Resistance
- Tricyclic Antidepressants May Reduce Cirrhosis Risk in Hepatitis C
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Efficacy of Adjuvanted vs Conventional Quadrivalent Flu Vaccine Compared
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Reduced Risk of Hepatocellular Carcinoma in DAA-Treated HCV Infection
- Paracetamol Overuse During Cold and Flu Season